Related Experiment Video

Updated: Feb 27, 2026

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring
07:35

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring

Published on: June 23, 2015

12.1K

[ADPKD and Heart]

Francesca Liut1, Claudia Izzi1, Nadia Dallera1

  • 1Seconda U.O. di Nefrologia e Dialisi, Università di Brescia, Italy.

Giornale Italiano Di Nefrologia : Organo Ufficiale Della Societa Italiana Di Nefrologia
|July 7, 2017
PubMed

Insights

Autosomal Polycystic Kidney Disease (ADPKD) is an inherited kidney disease affecting the heart and blood vessels. Early hypertension management with ACE inhibitors or ARBs can reduce cardiovascular risks in ADPKD patients.

Area of Science:

  • Nephrology
  • Cardiology
  • Genetics

Background:

  • Autosomal Polycystic Kidney Disease (ADPKD) is the most prevalent inherited renal disorder, stemming from mutations in PKD1 or PKD2.
  • ADPKD is a systemic condition impacting kidneys, liver, heart, and vasculature, leading to cyst formation and renal parenchyma destruction.
  • Cardiovascular complications, including hypertension and left ventricular hypertrophy, are frequent in ADPKD patients, contributing significantly to morbidity and mortality.

Purpose of the Study:

  • This review focuses on the cardiovascular manifestations in patients diagnosed with ADPKD.
  • To highlight the importance of managing hypertension in ADPKD to mitigate cardiovascular risks.

Main Methods:

  • Literature review of studies on ADPKD and its cardiovascular implications.
  • Analysis of current treatment guidelines for hypertension in ADPKD patients.

Main Results:

  • Hypertension is a prevalent cardiovascular issue in ADPKD, increasing the risk of serious complications.
  • Left ventricular hypertrophy, valvular abnormalities, and intracranial aneurysms are common extrarenal manifestations.
  • ACE inhibitors and angiotensin II receptor antagonists are recommended as first-line antihypertensive agents.

Conclusions:

  • Effective management of hypertension is crucial for reducing cardiovascular morbidity and mortality in ADPKD.
  • Targeted antihypertensive therapies can improve cardiovascular outcomes for individuals with ADPKD.
  • Further research into the specific cardiovascular risks and management strategies for ADPKD is warranted.

Keywords:
ADPKDhypertensionrenin-angiotensin-aldosterone system

More Related Videos

Implementing Patch Clamp and Live Fluorescence Microscopy to Monitor Functional Properties of Freshly Isolated PKD Epithelium08:46

Implementing Patch Clamp and Live Fluorescence Microscopy to Monitor Functional Properties of Freshly Isolated PKD Epithelium

Published on: September 1, 2015

10.3K
A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats07:31

A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats

Published on: December 2, 2016

10.7K

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
667
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
474
Pharmacokinetic–Pharmacodynamic Relationship: Exposure, Response and Effect01:26

Pharmacokinetic–Pharmacodynamic Relationship: Exposure, Response and Effect

The pharmacokinetic-pharmacodynamic (PK-PD) relationship describes the intricate link between drug exposure, efficacy, and toxicity, forming the foundation for optimal dosing regimens. This relationship uses mathematical modeling to characterize drug concentration-effect dynamics, ensuring precise therapeutic outcomes.Exposure represents the pharmacokinetic aspect of the PK-PD relationship, denoting the drug amount that elicits a biological response. It is typically quantified by administered...
71
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
471
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
565
cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
8.7K